Floatz logo

Empagliflozin

Molecular Mechanisms of Pharmacological Action

Yonsei UniversitySmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Molecular Mechanisms of Pharmacological Action cohort.

Asset / SponsorPhaseRating
Guanfacine
Maimonides Medical Center
Phase 4BB
Pioglitazone
Yonsei University
Phase 4BB
SACUBITRIL VALSARTAN
Silesian Centre for Heart Diseases
Phase 4BB
Sorafenib
Sichuan Cancer Hospital and Research Institute
Phase 2B
PROPRANOLOL
Tianjin Medical University General Hospital
Phase 2CCC

View all 15 →

Same molecule, other indications

Empagliflozin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
Hypoglycemic AgentsDormant
BBB
Indicative ·
75 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →